Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia

International Journal of Antimicrobial Agents

Volumn 40, Issue 5, 2012, Pages 434-439

  Jaruratanasirikul, Sutep ^a   Wongpoowarak, Wibul ^a   Kositpantawong, Narongdet ^a   Aeinlang, Nanchanit ^a   Jullangkoon, Monchana ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Carbapenem; Doripenem; Pharmacodynamics; Pharmacokinetics pharmacodynamics; Population pharmacokinetics; Ventilator associated pneumonia

Indexed keywords

DORIPENEM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INFUSION RATE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROBABILITY OF TARGET ATTAINMENT; RANDOMIZED CONTROLLED TRIAL; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CRITICAL ILLNESS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; TIME FACTORS;

EID: 84867405492     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.07.014     Document Type: Article

References (31)

1. A.M. Nicasio, J.L. Kuti, and D.P. Nicolau The current state of multidrug-resistant Gram-negative bacilli in North America Pharmacotherapy 28 2008 235 249
2. G.H. Talbot, J. Bradley, J.E. Edwards Jr., D. Gilbert, M. Scheld, and J.G. Bartlett Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin Infect Dis 42 2006 657 668
3. S.J. Keam Doripenem: a review of its use in the treatment of bacterial infections Drugs 68 2008 2021 2057
4. W.A. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 1995 89 96
5. B. Vogelman, S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W.A. Craig Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J Infect Dis 158 1988 831 847
6. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996;153:1711-25.
7. J.A. Roberts, A. Kwa, P. Montakantikul, C. Gomersall, J.L. Kuti, and D.P. Nicolau Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program - Asia-Pacific Region Int J Antimicrob Agents 37 2011 225 229
8. F.S. Taccone, P.F. Laterre, T. Dugernier, H. Spapen, I. Delattre, and X. Wittebole Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock Crit Care 14 2010 R126
9. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
10. T.M. File Jr. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines Clin Infect Dis 51 Suppl. 1 2010 S42 S47
11. K. Ikeda, K. Ikawa, N. Morikawa, K. Kameda, N. Urakawa, and H. Ohge Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection J Chromatogr B Analyt Technol Biomed Life Sci 867 2008 20 25
12. J.H. Mathews Numerical methods for computer science, engineering and mathematics 1987 Prentice-Hall International, Inc. London, UK
13. J. Li, and R.R. Rhinehart Heuristic random optimization Comput Chem Eng 22 1998 427 444
14. N. Worakul, W. Wongpoowarak, and P. Boonme Optimization in development of acetaminophen syrup formulation Drug Dev Ind Pharm 28 2002 345 351
15. G.E.P. Box, and M.E. Muller A note on the generation of random normal deviates Ann Math Statist 29 1958 610 611
16. P. Nandy, M.N. Samtani, and R. Lin Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients Antimicrob Agents Chemother 54 2010 2354 2359
17. E. Kikuchi, J. Kikuchi, Y. Nasuhara, S. Oizumi, A. Ishizaka, and M. Nishimura Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions Antimicrob Agent Chemother 53 2009 2799 2803
18. D.R. Baldwin, D. Honeybourne, and R. Wise Pulmonary disposition of antimicrobial agents: methodological considerations Antimicrob Agents Chemother 36 1992 1171 1175
19. J.W. Mouton, P.G. Ambrose, G. Kahlmeter, M. Wikler, and W.A. Craig Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing C.H. Nightingale, P.G. Ambrose, G.L. Drusano, T. Murakawa, Antimicrobial pharmacodynamics in theory and clinical practice 2007 Informa Healthcare New York, NY 21 44
20. G.L. Drusano Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl. 1 2003 S42 S50
21. V.H. Tam, P.S. Mckinnon, R.L. Akins, M.J. Rybak, and G.L. Drusano Pharmacodynamics of cefepime in patients with Gram-negative infections J Antimicrob Chemother 50 2002 425 428
22. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501
23. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B. McWhinney, and J. Ungerer Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 2011 10.1378/chest.11-1671 [Epub ahead of print]
24. D.S. McKindley, B.A. Boucher, M.M. Hess, M.A. Croce, and T.C. Fabian Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia Pharmacotherapy 16 1996 924 931
25. S.A. Van Wart, D.R. Andes, P.G. Ambrose, and S.M. Bhavnani Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients Diagn Microbiol Infect Dis 63 2009 409 414
26. K. Ikawa, N. Morikawa, S. Uehara, K. Monden, Y. Yamada, and N. Honda Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients Int J Antimicrob Agents 33 2009 276 279
27. US Food and Drug Administration. FDA statement on recently terminated clinical trial with Doribax (doripenem). http://www.fda.gov/Drugs/DrugSafety/ ucm285883.htm [accessed 12.04.12].
28. J. Justo, M.H. Gotfried, K. Deyo, P. Fischer, L.H. Danziger, and K.A. Rodvold Doripenem intrapulmonary pharmacokinetics in healthy adult subjects 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2011 2011 ASM Press Chicago [poster A1-1748]
29. R.E. Ariano, A. Nyhlen, J.P. Donnelly, D.S. Sitar, G.K.M. Harding, and S.A. Zelenitsky Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia Ann Pharmacother 39 2005 32 38
30. J.A. Roberts, C.M.J. Kirkpatrick, and J. Lipman Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients J Antimicrob Chemother 66 2011 227 231
31. J.H. Martin, M.F. Fay, A. Udy, J. Roberts, C. Kirkpatrick, and J. Ungerer Pitfalls of using estimations of glomerular filtration rate in an intensive care population Intern Med J 2010 10.1111/j.1445-5994.2010.02160.x [Epub ahead of print]